Treats relapsed or refractory follicular lymphoma after two or more lines of systemic…. Sold as Lunsumio, Lunsumio Velo. Every FDA application for this active ingredient. Boxed warning Orphan exclusivity to Dec 22, 2029
As of Nov 22, 2026, FDA lists 1 application for Mosunetuzumab-axgb (sold as Lunsumio, Lunsumio Velo), first approved Dec 22, 2022, with 2 new uses approved and 0 published complete response letters.
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Dec 22, 2022 | Lunsumio, Lunsumio VeloBLA 761263 · New molecular entity | Genentech | 3 | Marketed |
| Lunsumio | Part B | $32.8M | +28% | 273 |
| Lunsumio | Part D | $0 | −100% | 0 |
Of the 5 whose ending is known, 20% met their primary endpoint, 0% missed it and 80% stopped early.
| Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan TrialMantle Cell Lymphoma · University of Washington | Phase 2 | Not yet recruiting | Nov 2, 2026 |
| Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With TreatmentRecurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Nodal Marginal Zone Lymphoma · SWOG Cancer Research Network | Phase 2 | Not yet recruiting | Jun 10, 2026 |
| Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone LymphomaExtranodal Marginal Zone Lymphoma · Izidore Lossos, MD | Phase 2 | Recruiting | Aug 26, 2024 |
| Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular LymphomaRecurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma · City of Hope Medical Center | Phase 2 | Recruiting | Jun 11, 2024 |
| Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell LymphomaAnn Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma · University of Washington | Phase 2 | Recruiting | Jun 4, 2024 |
| Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular LymphomaClassic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features · National Cancer Institute (NCI) | Phase 3 | Recruiting | Mar 29, 2024 |
| Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell LymphomaDiffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma · OHSU Knight Cancer Institute | Phase 1 / Phase 2 | Recruiting | Feb 8, 2024 |
| Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma · National Cancer Institute (NCI) | Phase 1 | Recruiting | Aug 29, 2023 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA